November 6, 2020
During Blood Cancer Awareness Month, Know AML spoke to Gail Roboz, a world-leading doctor in acute myeloid leukemia who is based at Weill Cornell Medicine, New York, US. We asked, "What options are there for patients with the SRSF2 mutation?" In this video, Gail explains that although SRSF2 mutations are not uncommon in AML, there are no specific trials investigating this. However, there are some ongoing trials targeting the spliceosome.